Plasma membrane calcium ATPase proteins as novel regulators of signal transduction pathways. by Holton, Mary Louisa et al.
Plasma membrane calcium ATPase proteins as novel 
regulators of signal transduction pathways
Mary Louisa Holton, Weiguang Wang, Michael Emerson, Ludwig Neyses, Angel L Armesilla
201 June 26, 2010|Volume 1|Issue 6|WJBC|www.wjgnet.com
Mary Louisa Holton, Angel L Armesilla, Molecular Pharma-
cology Group, Department of Pharmacy, Research Institute in 
Healthcare Sciences, Room MA 228, School of Applied sciences, 
University of Wolverhampton, WV1 1SB, Wolverhampton, 
United Kingdom
Weiguang Wang, Oncology Group, Research Institute in Health-
care Sciences, School of Applied Sciences, University of Wolver-
hampton, Wulfruna Street, WV1 1SB, Wolverhampton, 
United Kingdom
Michael Emerson, National Heart and Lung Institute, Imperial 
College London, Exhibition Road, SW7 2AZ, London, 
United Kingdom
Ludwig Neyses, Cardiovascular Research Group, Manchester 
Academic Health Science Centre, Biomedical Research Centre 
and School of Biomedicine, University of Manchester, M13 9PT, 
Manchester, United Kingdom
Author contributions: Holton ML and Armesilla AL wrote the 
manuscript; Wang W, Emerson M and Neyses L corrected and 
critically read the manuscript.
Supported by The Breast Cancer Campaign and the Research 
Institute in Healthcare Sciences (Armesilla AL); The Wellcome 
Trust (Emerson M)
Correspondence to: Angel L Armesilla, PhD, Molecular Phar-
macology Group, Department of Pharmacy, Research Institute in 
Healthcare Sciences, Room MA 228, School of Applied sciences, 
University of Wolverhampton, WV1 1SB, Wolverhampton, 
United Kingdom. a.armesilla@wlv.ac.uk
Telephone: +44-1902-322756  Fax: +44-1902-323465
Received: May 18, 2010           Revised: June 22, 2010
Accepted: June 24, 2010
Published online: June 26, 2010
Abstract
Emerging evidence suggests that plasma membrane 
calcium ATPases (PMCAs) play a key role as regula-
tors of calcium-triggered signal transduction pathways 
via  interaction with partner proteins. PMCAs regulate 
these pathways by targeting specific proteins to cel-
lular sub-domains where the levels of intracellular free 
calcium are kept low by the calcium ejection properties 
of PMCAs. According to this model, PMCAs have been 
shown to interact functionally with the calcium-sensitive 
proteins neuronal nitric oxide synthase, calmodulin-
dependent serine protein kinase, calcineurin and endo-
thelial nitric oxidase synthase. Transgenic animals with 
altered expression of PMCAs are being used to evaluate 
the physiological significance of these interactions. To 
date, PMCA interactions with calcium-dependent partner 
proteins have been demonstrated to play a crucial role 
in the pathophysiology of the cardiovascular system via  
regulation of the nitric oxide and calcineurin/nuclear 
factor of activated T cells pathways. This new evidence 
suggests that PMCAs play a more sophisticated role 
than the mere ejection of calcium from the cells, by act-
ing as modulators of signaling transduction pathways.
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INTRODUCTION
Calcium is well known to play a pivotal role in the regula-
tion of  cellular physiology[1]. Tight control of  intracellular 
calcium homeostasis is essential for normal cellular func-
tion. The plasma membrane calcium ATPases (PMCAs) 
contribute to the maintenance of  appropriate cytoplas-
mic calcium levels by removing calcium from the cell to 
the extracellular environment[2]. There are four different 
PMCA isoforms (PMCA1-4) that are encoded by four 
independent genes[3-9]. PMCA1 and 4 are expressed ubiq-
uitously, whereas the expression of  PMCA2 and 3 is re-
stricted to specific cells and tissues[4,9]. Additional isoform 
diversity is generated by alternative splicing of  primary 
transcripts, which raises more than 20 different PMCA 
versions[10]. Structurally, PMCAs consist of  10 transmem-
brane domains, two major intracellular loops, and N- and 
C-cytoplasmic domains[11].
In addition to their traditional role as calcium trans-
porters, a growing body of  evidence suggests that PM-
CAs perform more specialized functions by establishing 
molecular interactions between their intracellular domains 
and cytoplasmic partner proteins. In this context, we and 
others have identified interactions between the cytoplas-
mic C-terminal end of  PMCA and a number of  PDZ 
[postsynaptic density 95 (PSD-95), Drosophila discs 
large protein and zona occludens-1] domain-containing 
proteins such as, members of  the membrane-associated 
guanylate kinase (MAGUK) family[12,13], the cytoskeletal 
CLP36 protein[14], the Na+/H+ exchanger regulatory fac-
tor-2[15], the PMCA-interacting single-PDZ domain pro-
tein[16], neuronal nitric oxide synthase (nNOS, NOS-1)[17], 
the calcium/calmodulin-dependent serine protein kinase 
(CASK)[18], and the scaffold protein Ania-3/Homer[19]. 
Interactions with molecular partners are not limited to 
the C-terminal domain of  PMCAs but also involve other 
intracellular domains. In fact, the big catalytic intracellular 
domain located between transmembrane regions 4 and 5 
of  PMCA has been reported to interact with the tumor 
suppressor protein Ras-associated factor 1 (Rassf1)[20], the 
calcium-dependent phosphatase calcineurin[21], the cyto-
skeletal scaffolding protein α-1 syntrophin[22], and endo-
thelial NOS (eNOS; NOS-3)[23]. Finally, the N-terminal 
region of  PMCA1, 3 and 4 has been shown to interact 
with the isoform ε of  the 14-3-3 protein[24,25]. 
These interactions fulfill several purposes, from tar-
geted localization of  the pump or interaction partner to 
a particular subcellular domain[15], to the modification of  
the functional activity of  PMCA[24,25] or the associated 
protein[17,18,20,21,23]. In this sense, interaction with PMCA 
has been reported to downregulate the enzymatic activ-
ity of  signaling partner proteins that play key roles in 
the transduction of  signals within the cell[17,18,21-23]. These 
findings suggest that PMCAs might participate in the 
regulation of  signal transduction pathways. According to 
this idea, PMCAs have been found in caveolae and lipid-
rafts in different cellular types[26-29]. It is well established 
that caveolae and lipid-rafts are specialized membrane 
sub-domains that are enriched in a variety of  molecules 
implicated in the integration and regulation of  cellular 
signaling events[30]. The sub-cellular localization of  PM-
CAs in caveolae is, therefore, well in agreement with 
their putative role as signaling regulators.
This review outlines recent evidence that supports 
the novel role for PMCA as a regulator of  signal trans-
duction pathways, and highlights the first approaches to 
analyze the functional significance of  the interactions 
between PMCA and partner proteins using transgenic 
animal models.
PMCAs AS REGULATORS OF CALCIUM-
DEPENDENT SIGNAL TRANSDUCTION 
PATHWAYS
A number of  the PMCA partner proteins identified so 
far are well-established calcium-regulated enzymes that 
participate in the transduction of  calcium signals within 
the cell (Table 1)[17,18,21,23]. It is thought that PMCAs in-
hibit the activity of  these molecules by tethering them 
to low calcium micro-domains that are created by the 
calcium extrusion function of  the pump (Figure 1). Two 
different sets of  data support this hypothesis. (1) PM-
CAs have been found to be concentrated up to 25-fold 
in caveolae[26,29]. Highly concentrated PMCA clusters 
might create small cellular microenvironments where 
intracellular calcium is maintained at a low level by the 
calcium-extrusion activity of  PMCAs. In this location, 
the activity of  calcium-dependent enzymes is downregu-
lated; (2) The interaction between PMCAs and partner 
proteins is essential for downregulation of  the activity of  
the associated protein. As described below, experiments 
in which the interaction between PMCA and its interac-
tion partner was disrupted, or impaired, reversed the 
PMCA-mediated inhibition of  the activity of  the partner 
protein. Importantly, these experiments didnot alter the 
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Figure 1  Model of plasma membrane calcium ATPase (PMCA) as a regulator 
of signal transduction pathways. PMCA pumps calcium out of the cell and 
generates a microenvironment where the intracellular calcium concentrations 
are very low. Interaction with the intracellular domains of PMCA tethers partner 
proteins to this low-calcium microenvironment, which results in downregulation 
of the enzymatic activity of calcium/calmodulin-dependent proteins. Ca2+/CaM-
dep, calcium/calmodulin-dependent enzyme.
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calcium-extruding properties of  PMCAs that were still 
fully active, which demonstrates that general clearance 
of  calcium by PMCAs is not sufficient to modify the ac-
tivity of  the partner proteins, and that the localization of  
the partner proteins to a particular sub-domain with low 
calcium levels is a more plausible mechanism. 
In concurrence with this hypothesis, PMCAs have 
been reported to regulate NO- and calcineurin-depen-
dent signal transduction pathways via interaction with 
NOSs and calcineurin, respectively.
PMCA negatively modulates NO-dependent signaling
The first evidence to show the involvement of  PMCAs 
in the regulation of  NO signaling was reported by Schuh 
et al[17] almost 10 years ago. Ectopic expression of  recom-
binant human PMCA4b and nNOS in HEK-293 cells 
demonstrated the interaction between the two proteins[17]. 
Binding of  PMCA4b to nNOS resulted in significant in-
hibition of  nNOS activity, which suggests that PMCA4b 
is implicated in the modulation of  NO synthesis and, 
therefore, NO-dependent signaling[17]. 
Further to this first observation, immunoprecipita-
tion experiments with cardiac proteins have demonstrat-
ed that endogenous PMCA4b and nNOS form a ternary 
complex together with α-1 syntrophin[22]. PMCA and 
α-1 syntrophin act synergistically to regulate negatively 
nNOS activity[22], which introduces a new level of  regula-
tion on the PMCA-mediated control of  nNOS activity. 
The relevant role of  NO in the control of  cardiovas-
cular physiology[31] has prompted the groups of  Neyses 
and Husein to investigate the physiological relevance of  
the PMCA4b/nNOS interaction in the cardiovascular 
system. Work by these groups has demonstrated the in-
teraction between endogenous PMCA4b and nNOS in 
mouse cardiomyocytes and smooth muscle cells[22,32-35]. 
The generation of  transgenic mice with altered expres-
sion of  PMCA4b in cardiovascular cells has corroborat-
ed the functionality of  the PMCA4b/nNOS interaction 
in a physiological system. 
Transgenic mice that express human PMCA4b un-
der the control of  the arterial-smooth-muscle-specific 
SM22α promoter have shown depressed nNOS activi-
ty[33], in association with increased vasomotor responsive-
ness and blood pressure[32,33], which indicates that PMCA 
plays a significant role in the regulation of  vascular tone. 
Likewise, to investigate the physiological importance 
of  the PMCA/nNOS interaction as a regulator of  NO 
signaling in cardiac physiology, Oceandy et al[34] overex-
pressed human PMCA4b in the heart of  transgenic mice 
under the control of  the myosin light chain (MLC2v) 
promoter. β-adrenergic stimulation of  cardiac contractil-
ity was significantly attenuated in the animals that over-
expressed PMCA4b[34]. To ascertain that this effect was a 
consequence of  PMCA4b-mediated inhibition of  nNOS, 
Oceandy et al[34] also generated mice that overexpressed 
PMCA4 ct120 (a mutant form of  human PMCA4b that 
lacks 120 amino acid residues at the C terminus, including 
the PDZ-binding motif[36]) in the heart of  the transgenic 
animals. PMCA4 ct120 is very active as a calcium pump[36] 
but it is unable to downregulate nNOS activity due to a 
lack of  interaction[17]. Animals that overexpressed this 
non-nNOS binding form of  PMCA4 exhibited normal 
β-adrenergic stimulation of  cardiac contractility[34], which 
suggests that the PMCA4b/nNOS interaction is indeed 
involved in the inotropic response of  mouse cardiomyo-
cytes to β-adrenergic stimuli. Moreover, when wild-type 
animals or transgenic mice that expressed the PMCA4 
ct120 mutant were treated with the specific nNOS in-
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Table 1  Functional interactions between PMCA and calcium-dependent partner proteins
Protein partner Domain of PMCA implicated in the 
interaction
Domain of partner 
protein implicated in 
the interaction
Functional consequence of 
the interaction
Proposed mechanism of regulation
nNOS, NOS-1 C-terminal PDZ-binding domain PDZ domain Decrease nNOS activity, 
decrease NO production
PMCA interactions tethers partner protein 
to a low calcium micro-environment, 
this results in inhibition of the enzymatic 
activity of the partner proteins
CASK C-terminal PDZ-binding domain PDZ domain Decrease in T-element- 
dependent transcriptional 
activit
PMCA interactions tethers partner protein 
to a low calcium micro-environment, 
the complex CASK/Tbr-1 cannot be 
established
eNOS, NOS-3 Proximal region of the big, catalytic 
intracellular loop located between 
transmembrane domains 4 and 5 
(amino acids 462-684 and 428-651 of 
PMCA2 and 4, respectively)
Region 735-934 of 
eNOS
Decrease eNOS activity, 
decrease NO production
PMCA interactions tethers partner protein 
to a low calcium micro-environment, 
this results in inhibition of the enzymatic 
activity of the partner proteins
Calcineurin A Proximal region of the big, catalytic 
intracellular loop located between 
transmembrane domains 4 and 5 
(amino acids 462-684 and 428-651 of 
PMCA2 and 4, respectively)
Region 58-143 of 
calcineurin A
Decrease in calcineurin/
NFAT-dependent 
transcriptional activity
PMCA interactions tethers partner protein 
to a low calcium micro-environment, 
this results in inhibition of the enzymatic 
activity of the partner proteins
PMCA: Plasma membrane calcium ATPase; NOS: Nitric oxide synthase; nNOS: Neuronal NOS; eNOS: Endothelial NOS; CASK: Calmodulin-dependent 
serine protein kinase.
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hibitor N-propyl-L-arginine (L-nPA), the β-adrenergic-
induced response in cardiac contractility was inhibited[34], 
however, L-nPA had no significant effect in the response 
of  PMCA4b-overexpressing mice[34].
The molecular analysis of  cardiomyocytes from 
PMCA4b-overexpressing transgenic animals has also 
revealed the PMCA/nNOS-downstream effectors that 
are implicated in the modulation of  the β-adrenergic re-
sponse in cardiac cells[35]. It seems that PMCA-mediated 
reduction of  nNOS activity leads to a decrease in NO 
levels and a concomitant reduction in the levels of  
cGMP produced by the soluble guanylyl cyclase. This re-
duction in the cGMP levels translates into a decrease in 
phosphodiesterase activity that prevents degradation of  
cAMP and results in strong elevation of  cAMP intracel-
lular levels in cardiomyocytes. Increased cAMP levels ac-
tivate the cAMP-dependent protein kinase, which leads 
to enhanced phosphorylation of  its major substrates in 
cardiac cells, the proteins phospholamban and cardiac 
troponin I (cTn I)[35]. This cascade of  molecular events, 
which ends with increased phosphorylation of  phos-
pholamban and cTn I, explains the reduced β-adrenergic 
response that is observed in the cardiac-specific trans-
genic mice that overexpress PMCA4b[34] (Figure 2).
A recent study by Beigi et al[37] has shown that cardiac 
PMCA4b and nNOS are implicated in the formation 
of  a ternary complex with the nNOS adaptor protein 
CAPON (carboxy-terminal PDZ ligand of  NOS1). The 
authors have demonstrated that PMCA interacts with 
CAPON in cardiac cells. The interaction between the 
two proteins is dependent on the presence of  nNOS and 
increases following myocardial infarction. The complex 
CAPON/nNOS (initially located in the sarcoplasmic 
reticulum) redistributes to caveolae after myocardial in-
farction[37]. The presence of  PMCA in cardiac caveolae[28] 
suggests that the pump can be involved in the redistribu-
tion of  nNOS that occurs after myocardial infarction via 
its interaction with the complex CAPON/nNOS. Further 
investigations are necessary to elucidate if  the interaction 
PMCA/CAPON/nNOS results in a decrease in nNOS 
activity in injured myocardium.
Our work in endothelial cells has recently shown that 
PMCAs interact with eNOS [23]. This interaction has been 
mapped to the catalytic, big intracellular loop located be-
tween transmembrane domains 4 and 5 of  PMCAs, and 
the region 735-934 of  eNOS. PMCA/eNOS association 
results in a significant decrease in eNOS activity, and 
subsequent NO production in resting and acetylcholine-
stimulated endothelial cells. A first insight into the mo-
lecular mechanisms responsible for inhibition of  eNOS 
activity has shown that interaction with PMCA leads to 
an increase in the phosphorylation status of  the residue 
Thr-495 of  eNOS[23]. Phosphorylation of  Thr-495 is 
well known to inhibit eNOS activity[38], which suggests 
that PMCA negatively regulates eNOS activity by pro-
moting Thr-495 phosphorylation. The in vivo analysis of  
the physiological relevance of  this interaction must wait 
for the generation of  genetically modified animals with 
altered expression of  PMCAs in endothelial cells.
PMCA inhibits the calcineurin/nuclear factor of activated 
T cells signal transduction pathway
More evidence in support of  a role for PMCA in the 
regulation of  calcium-dependent signaling pathways has 
come from the identification of  a functional interaction 
between PMCA and the catalytic subunit of  the calcium-
sensitive serine-threonine phosphatase calcineurin[21,23,39,40]. 
Calcineurin plays a crucial role in the coupling of  calcium 
signals to cellular responses. Increments in the levels of  
cytoplasmic calcium result in activation of  calcineurin, 
which in turn dephosphorylates specific target sub-
strates[41]. The best-characterized substrate of  calcineurin 
is the nuclear factor of  activated T cells (NFAT) family 
of  transcription factors[42]. NFATs are expressed as con-
stitutively phosphorylated proteins in the cytoplasm of  
resting cells. Activated calcineurin mediates dephosphor-
ylation of  the NFAT transcription factors and their sub-
sequent translocation from the cytoplasm to the nucleus. 
Once in the nucleus, NFATs bind to specific sequences 
in the regulatory regions of  target genes and switch on 
their expression[42]. Activation of  the calcineurin/NFAT 
pathway has been implicated in the progression of  a 
large variety of  processes including: T-cell activation 
and differentiation[43], osteoblast growth and differentia-
tion[44], skeletal muscle growth and development[45], neural 
development and axon growth[46], beta-cell growth and 
function[47], heart valve morphogenesis[48], and cardiac hy-
pertrophy[49]. The broad spectrum of  biological processes 
that are orchestrated by calcineurin/NFAT-mediated sig-
nals underlines the importance of  the proper regulation 
of  this pathway. We and others have recently shown that 
the interaction between PMCA and calcineurin leads to 
inhibition of  the calcineurin/NFAT activity[21,39,40], which 
indicates that PMCA plays a relevant role in the control 
of  this pathway. To evaluate the in vivo significance of  this 
interaction, Wu et al[40] have generated inducible, cardiac-
specific, PMCA4b transgenic mice. Overexpression of  
the PMCA4b isoform in the heart antagonizes cardiac 
hypertrophy induced by transverse aortic constriction or 
phenylephrine/angiotensin Ⅱ infusion[40]. In contrast, 
Oceandy et al[34] have found that mice that overexpress 
PMCA4b in the heart display an increased hypertrophic 
response after chronic stimulation with isoproterenol. 
The reasons behind this discrepancy are not clear at pres-
ent. Further investigations in cardiac, and other tissues 
where the calcineurin/NFAT pathway modulates biologi-
cal responses, are required to gain a full understanding of  
the role of  PMCA as a cellular regulator of  calcineurin.
PMCA downregulates CASK/Tbr-1 signaling
Additional evidence for the role of  PMCA as a regulator 
of  calcium signaling has been provided by the charac-
terization of  a molecular interaction between PMCA4b 
and CASK in protein extracts isolated from rat brain and 
kidney[18]. CASK is a MAGUK family member and, like 
other members of  the family mentioned before, contains 
a PDZ-domain that is responsible for binding to PM-
CA4b. CASK can form a molecular complex with the 
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transcription factor Tbr-1[50]. Once formed, the complex 
CASK/Tbr-1 enters the nucleus and binds to T-element 
sequences (AATTTCACACCTAGGTGTGAAATT) 
that are located in the promoter regions of  specific target 
genes[50]. PMCA interaction with CASK results in a dra-
matic reduction (80% decrease) in T-element-dependent 
transcriptional activity[18]. As described above for the 
PMCA-mediated regulation of  other partner proteins, 
PMCA4b seems to modulate CASK/Tbr-1 functionality 
by depletion of  calcium in the proximity of  the pump. 
Supporting this idea, a mutated PMCA4b (Asp672 → Glu) 
(with the calcium pumping activity severely compromised 
but still able to interact with CASK[51]) or the PMCA4 
ct120 mutant (which retains full calcium extrusion capa-
bilities but is unable to bind to CASK) had only a small 
influence on the transcriptional activity of  a T-element-
driven luciferase reporter vector[18]. The characteriza-
tion of  a functional interaction between PMCA4b and 
CASK/Tbr-1 reinforces the link between PMCAs and 
the regulation of  calcium-dependent gene transcription 
that is suggested by the PMCA/calcineurin interaction.
The molecular events behind the PMCA-mediated 
downregulation of  CASK/Tbr-1 activity are not under-
stood at present. It has been shown that the calmodulin-
binding site of  CASK binds calmodulin in a calcium-
dependent manner[52]. It is tempting to speculate that 
calcium/calmodulin binding to CASK might alter the 
conformation of  the protein, which causes its release 
from PMCA and leads to its binding to Tbr-1. CASK/
Tbr-1 would then travel together to the nucleus and acti-
vate the expression of  target genes. In this case, PMCA-
mediated targeting of  CASK to a low calcium cellular 
sub-domain would not be directly involved in regulating 
the catalytic activity of  the partner protein (as is the case 
for NOS or calcineurin), but would control calcium-de-
pendent interactions between the partner protein CASK 
and its effector Tbr-1. The physiological relevance of  
the PMCA-mediated regulation of  CASK/Tbr-1 signal-
ing requires further investigation.
CONCLUSION AND FUTURE 
PERSPECTIVES
From the studies that we have discussed in this review, 
we can conclude that PMCAs play a significant role in the 
negative regulation of  signal transduction pathways. In 
some instances, PMCAs seem to create local low calcium 
microenvironments that decrease the catalytic activity of  
calcium-sensitive signal transduction proteins. In other 
cases, it seems that low calcium levels might impair the 
interaction between key signaling proteins and their effec-
tors. The use of  transgenic animal models with modified 
expression of  PMCA proteins in cardiovascular tissues 
is starting to reveal the physiological functionality of  the 
PMCA/nNOS and PMCA/calcineurin interactions in the 
regulation of  cardiovascular signal transduction (Figure 2), 
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although additional work must be conducted in the future 
in other organs and cellular types.
PMCA-mediated low-calcium microenvironments 
might be the result of  localization of  the pump to spe-
cific plasma membrane microdomains. In this sense, 
the interaction between the PSD-95 scaffolding protein 
and PMCA4b has been shown to induce the formation 
of  high-density PMCA4b clusters in the plasma mem-
brane[53]. Although the physiological consequences of  the 
PSD-95/PMCA4b interaction remain to be determined, 
PSD-95 has also been reported to induce clustering of  
other proteins (such as potassium channels and neu-
rotransmitter receptors) that play an important role in 
the regulation of  synaptic signal transduction[54-56], which 
suggests that PMCA4b participates in the regulation 
of  calcium signaling in the synaptic nerve terminals via 
PSD-95-induced clustering. In support of  the function 
of  PMCA as a regulator of  calcium signaling at synapses, 
Garside et al[57] have analyzed PMCA interactions in syn-
apse-enriched brain tissue from rats, and have found that 
PMCA2 interacts with the postsynaptic protein PSD-95, 
and the NMDA glutamate receptor subunits NR1 and 
NR2a. At the pre-synapse, PMCA2 interacts with the 
presynaptic protein syntaxin-1A. By establishing interac-
tions with synaptic partner proteins, PMCAs might form 
part of  signaling macromolecular complexes and par-
ticipate in the regulation of  synaptic calcium-dependent 
signal transduction pathways, via control of  local calcium 
dynamics at specific sites of  the synapse.
To date, no studies have evaluated the influence of  
calcium in the interaction between PMCA and partner 
proteins. It is well recognized that the intracellular lev-
els of  calcium play a dynamic role in the regulation of  
protein-protein interactions, for instance, increments in 
the intracellular levels of  calcium/calmodulin abolish the 
interaction between eNOS and caveolin-1 and lead to ac-
tivation of  eNOS[58]. In a similar way, increments in intra-
cellular calcium might disrupt the PMCA/eNOS interac-
tion, which allows eNOS to escape from the low-calcium 
microdomain that is created by PMCA activity. This pos-
sibility introduces a new dimension to the regulation of  
partner proteins by PMCAs, and as such, requires further 
investigation.
PMCAs also seem to be involved in the regulation of  
other signaling pathways where the role of  calcium is not 
so evident, for example, in the regulation of  the Ras/Erk 
pathway via interaction with Rassf1A. In these cases, 
PMCA might act as a macromolecular protein organizer 
that recruits proteins to specific cellular domains. This 
function might be comparable to that of  the scaffold pro-
tein CNK1 in Ras-mediated apoptosis. CNK1 interacts 
with the signaling protein Ras[59]. Ras-promoted apoptosis 
requires the participation of  the Mst kinases. To place the 
Mst1/2 kinases in contact with Ras, CNK1 interacts with 
Rassf1 which, in turn, interacts with Mst1/2 kinases[59]. 
Disruption of  the interaction CNK1/Rassf1A disas-
sembles the complex and suppresses Ras-mediated apop-
tosis[59]. It seems entirely plausible that PMCAs might 
be playing a similar role as recruiters of  macromolecular 
signaling complexes in caveolae, and therefore, might be 
placing Rassf1 in contact with other signaling proteins. 
This exciting possibility deserves further investigation.
In summary, data from several groups support a nov-
el role for PMCA as a regulator of  signal transduction 
pathways. It will be interesting to exploit this new func-
tionality of  PMCA with therapeutic purposes through 
the design of  new drugs that regulate its activity. This 
strategy could be used to modulate essential biological 
processes in the cardiovascular system, and likely, other 
organs and tissues. 
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